{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:49:10Z","timestamp":1790797750134,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug\u2013resistant tuberculosis (DR\u2013TB) remains a major public health challenge in China, yet long\u2013term epidemiological data from key regions such as Hunan Province in South\u2013Central China are still limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to characterize the epidemiological trends, spatial distribution, and risk factors of Single drug\u2013resistant tuberculosis (SDR\u2013TB), poly\u2013drug\u2013resistant tuberculosis (PDR\u2013TB), multidrug\u2013resistant tuberculosis (MDR\u2013TB), rifampicin\u2013resistant tuberculosis (RR\u2013TB), and isoniazid\u2013resistant tuberculosis (INH\u2013R TB) in Hunan Province between 2014 and 2023, to inform region\u2013specific control strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>It was a retrospective analysis that was conducted on 6,597 laboratory\u2013confirmed DR\u2013TB cases. Data were obtained from the Provincial Tuberculosis Control Institute. All patients underwent phenotypic drug susceptibility testing. Independent risk factors for DR\u2013TB subtypes were identified through multivariable logistic regression, with adjusted odds ratios (ORs) and corresponding 95% confidence intervals (CIs) calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 6,597 patients with DR\u2013TB were included in this 10\u2013year analysis. Among them, 74.97% were male and 64.44% were farmers. The highest case burden was observed in the 50\u201359 age group (24.78%). Spatially, cases clustered mainly in the Changsha (16.39%), Shaoyang (13.78%), and Loudi (9.05%). The most common resistance subtypes were INH\u2013R TB (56.27%) and MDR\u2013TB (52.37%). The distribution of all DR\u2013TB subtypes varied significantly across age groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05), with peaks in middle\u2013aged and older adults. Over time, the detection rate of MDR\u2013TB was highest in 2018, while RR\u2013TB remained the most frequently detected resistance type. Multivariable analysis identified significant regional and demographic disparities. The eastern region of Hunan was associated with an increased risk of SDR\u2013TB (OR\u202f=\u202f1.334) and PDR\u2013TB (OR\u202f=\u202f1.208), whereas the western region carried the highest risk for MDR\u2013TB (OR\u202f=\u202f1.734). Female patients consistently showed lower risks of MDR\u2013TB (OR\u202f=\u202f0.819) and RR\u2013TB (OR\u202f=\u202f0.784) compared with males.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study presents a 10\u2013year epidemiological assessment of DR\u2013TB in Hunan Province, China, covering 2014\u20132023. A disproportionately high burden was observed among middle\u2013aged and older male farmers. The predominance of INH\u2013R TB and MDR\u2013TB, together with distinct regional and demographic risk profiles, underscores an urgent need to strengthen TB control measures. These results support the implementation of targeted interventions, including intensified screening in high\u2013risk populations and in high\u2013incidence areas, along with optimized treatment regimens, to curb the ongoing DR\u2013TB epidemic in South\u2013Central China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1771140","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:30:44Z","timestamp":1771828244000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Epidemiology of drug\u2013resistant tuberculosis in Hunan China over a 10\u2013year period"],"prefix":"10.3389","volume":"14","author":[{"given":"Yi","family":"Liu","sequence":"first","affiliation":[{"name":"Hunan Provincial Tuberculosis Prevention and Control Institute & Hunan Chest Hospital","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[{"name":"Hunan Provincial Tuberculosis Prevention and Control Institute & Hunan Chest Hospital","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Wan","sequence":"additional","affiliation":[{"name":"Hunan Provincial Tuberculosis Prevention and Control Institute & Hunan Chest Hospital","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Peng","sequence":"additional","affiliation":[{"name":"Guangzhou Huazhun Medical Laboratory Co., Ltd.","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Guo","sequence":"additional","affiliation":[{"name":"Hunan Provincial Tuberculosis Prevention and Control Institute & Hunan Chest Hospital","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[{"name":"Hunan Provincial Tuberculosis Prevention and Control Institute & Hunan Chest Hospital","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhou","sequence":"additional","affiliation":[{"name":"Hunan Provincial Tuberculosis Prevention and Control Institute & Hunan Chest Hospital","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Li","sequence":"additional","affiliation":[{"name":"Hunan Provincial Tuberculosis Prevention and Control Institute & Hunan Chest Hospital","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Duan","sequence":"additional","affiliation":[{"name":"Hunan Provincial Tuberculosis Prevention and Control Institute & Hunan Chest Hospital","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Hunan Provincial Tuberculosis Prevention and Control Institute & Hunan Chest Hospital","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Bai","sequence":"additional","affiliation":[{"name":"Hunan Provincial Tuberculosis Prevention and Control Institute & Hunan Chest Hospital","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Chen","sequence":"additional","affiliation":[{"name":"Hunan Provincial Tuberculosis Prevention and Control Institute & Hunan Chest Hospital","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangzhen","family":"Luo","sequence":"additional","affiliation":[{"name":"Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China","place":["Hengyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhong","family":"Tan","sequence":"additional","affiliation":[{"name":"Hunan Provincial Tuberculosis Prevention and Control Institute & Hunan Chest Hospital","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/S2468\u20132667(23)00063\u20134","article-title":"Taking tuberculosis out of the shadows","volume":"8","year":"2023","journal-title":"Lancet Public Health"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.ijid.2022.03.026","article-title":"Drug resistant TB \u2013latest developments in epidemiology, diagnostics and management","volume":"124","author":"Tiberi","year":"2022","journal-title":"Int J Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e0018019","DOI":"10.1128\/cmr.00180\u201319","article-title":"The changing paradigm of drug\u2013resistant tuberculosis treatment: successes, pitfalls, and future perspectives","volume":"35","author":"Dookie","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"100899","DOI":"10.1016\/S2666\u20135247(24)00131\u20139","article-title":"The catalogue of Mycobacterium tuberculosis mutations associated with drug resistance to 12 drugs in China from a nationwide survey: a genomic analysis","volume":"5","author":"Pei","year":"2024","journal-title":"Lancet Microbe"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/tropicalmed10010003","article-title":"Mapping drug\u2013resistant tuberculosis treatment outcomes in Hunan Province, China","volume":"10","author":"Akalu","year":"2024","journal-title":"Trop Med Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1128\/AAC.02426\u201314","article-title":"Prevalence and molecular characteristics of drug\u2013resistant Mycobacterium tuberculosis in Hunan, China","volume":"58","author":"Zhao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41579-024-01025-1","article-title":"Drug\u2013resistant tuberculosis: a persistent global health concern","volume":"22","author":"Farhat","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e69694","DOI":"10.7759\/cureus.69694","article-title":"Quantitative study of physical, social, psychological, and environmental challenges faced by patients with drug\u2013resistant tuberculosis","volume":"16","author":"Sahasrabudhe","year":"2024","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2666\u20135247(22)00359\u20137","article-title":"WHO'S global tuberculosis report 2022","volume":"4","author":"Bagcchi","year":"2023","journal-title":"Lancet Microbe"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"721817","DOI":"10.3389\/fpubh.2021.721817","article-title":"Drug\u2013resistant tuberculosis among children: a systematic review and meta\u2013analysis","volume":"9","author":"Song","year":"2021","journal-title":"Front Public Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/cid\/ciaa613","article-title":"Concordance of drug\u2013resistance profiles between persons with drug\u2013resistant tuberculosis and their household contacts: a systematic review and meta\u2013analysis","volume":"73","author":"Chiang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e0305930","DOI":"10.1371\/journal.pone.0305930","article-title":"Pharmaceutical cost dynamics for the treatment of rifampicin\u2013resistant tuberculosis in children and adolescents in South Africa, India, and the Philippines","volume":"19","author":"Wilkinson","year":"2024","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/jac\/dkaa470","article-title":"Nevirapine pharmacokinetics in HIV\u2013infected persons receiving rifapentine and isoniazid for TB prevention","volume":"76","author":"Podany","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"107173","DOI":"10.1016\/j.cct.2023.107173","article-title":"Using a medication event monitoring system to evaluate self\u2013report and pill count for determining treatment completion with self\u2013administered, once\u2013weekly isoniazid and rifapentine","volume":"129","author":"Scott","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11904\u2013021\u201300588\u20135","article-title":"COVID\u201319: impact on the HIV and tuberculosis response, service delivery, and research in South Africa","volume":"19","author":"Abdool Karim","year":"2022","journal-title":"Curr HIV AIDS Rep"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12038-025-00496-5","article-title":"The interplay of tuberculosis and COVID\u201319: insights into global health challenges","volume":"50","author":"Syal","year":"2025","journal-title":"J Biosci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/S2666\u20135247(23)00042\u20133","article-title":"Integrating tuberculosis and COVID\u201319 molecular testing in Lima, Peru: a cross\u2013sectional, diagnostic accuracy study","volume":"4","author":"MacLean","year":"2023","journal-title":"Lancet Microbe"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1405358","DOI":"10.3389\/fpubh.2024.1405358","article-title":"Analysis of epidemiological characteristics of extrapulmonary tuberculosis from south\u2013Central China","volume":"12","author":"Yu","year":"2024","journal-title":"Front Public Health"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1432071","DOI":"10.3389\/fpubh.2024.1432071","article-title":"Analysis on the epidemiological and drug resistance characteristics of osteoarticular tuberculosis in south\u2013Central China","volume":"12","author":"Fang","year":"2024","journal-title":"Front Public Health"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3760\/cma.j.cn112147\u201320211219\u201300904","article-title":"Prevalence and transmission of pyrazinamide\u2013resistant Mycobacterium tuberculosis in Hunan Province,China","volume":"45","author":"Liu","year":"2022","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"6778","DOI":"10.3390\/ijerph18136778","article-title":"Spatiotemporal patterns of tuberculosis in Hunan Province, China","volume":"18","author":"Alene","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1426503","DOI":"10.3389\/fpubh.2024.1426503","article-title":"Spatiotemporal analysis of tuberculosis in the Hunan Province, China, 2014\u20132022","volume":"12","author":"Huang","year":"2024","journal-title":"Front Public Health"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12879\u2013024\u201309106\u20135","article-title":"Determinants of drug\u2013resistant tuberculosis in Hunan province, China: a case\u2013control study","volume":"24","author":"Akalu","year":"2024","journal-title":"BMC Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e0292965","DOI":"10.1371\/journal.pone.0292965","article-title":"Genomic epidemiology analysis of drug\u2013resistant Mycobacterium tuberculosis distributed in Mexico","volume":"18","author":"Mej\u00eda\u2013Ponce","year":"2023","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e0097820","DOI":"10.1128\/mSphere.00978\u201320","article-title":"Molecular epidemiology of drug\u2013resistant Mycobacterium tuberculosis in Japan","volume":"6","author":"Mizukoshi","year":"2021","journal-title":"mSphere"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"110640","DOI":"10.1016\/j.ygeno.2023.110640","article-title":"Emergence and evolution of drug\u2013resistant Mycobacterium tuberculosis in eastern China: a six\u2013year prospective study","volume":"115","author":"Wang","year":"2023","journal-title":"Genomics"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2348505","DOI":"10.1080\/22221751.2024.2348505","article-title":"Transmission characteristics in tuberculosis by WGS: nationwide cross\u2013sectional surveillance in China","volume":"13","author":"Liu","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1186\/s12879\u2013022\u201307855\u20139","article-title":"Impact of molecular diagnostic tests on diagnostic and treatment delays in tuberculosis: a systematic review and meta\u2013analysis","volume":"22","author":"Lee","year":"2022","journal-title":"BMC Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.2147\/IDR.S415906","article-title":"Phenotypic drug resistance pattern and mutation characteristics of Mycobacterium tuberculosis from different body fluids among extra pulmonary patients presented in selected hospitals in Addis Ababa, Ethiopia","volume":"16","author":"Alehegn","year":"2023","journal-title":"Infect Drug Resist"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ijregi.2023.03.007","article-title":"Burden of mycobacterium tuberculosis and associated factors among presumptive extra pulmonary tuberculosis patients from selected health facilities, Addis Ababa, Ethiopia","volume":"7","author":"Alehegn","year":"2023","journal-title":"IJID Reg"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/tmi.14126","article-title":"Characteristics and risk factors of drug\u2013resistant tuberculosis in Sichuan, China: an observational study","volume":"30","author":"Han","year":"2025","journal-title":"Trop Med Int Health"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2174\/1568026621999201211200447","article-title":"Tuberculosis: an update on pathophysiology, molecular mechanisms of drug resistance, newer anti\u2013TB drugs, treatment regimens and host\u2013directed therapies","volume":"21","author":"Borah","year":"2021","journal-title":"Curr Top Med Chem"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4269\/ajtmh.21\u20130659","article-title":"Epidemiological characteristics and risk factors related to drug\u2013resistant tuberculosis in Luanda, Angola","volume":"106","author":"Borah","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jgar.2024.09.002","article-title":"Age and gender in drug resistance tuberculosis: a cross\u2013sectional case study at a national tuberculosis reference hospital in Nigeria","volume":"39","author":"Madaki","year":"2024","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1771140\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:30:46Z","timestamp":1771828246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1771140\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":34,"alternative-id":["10.3389\/fpubh.2026.1771140"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1771140","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"article-number":"1771140"}}